A Double Accolade for LOXAM’s CSR Policy: the 2019 Era Sustainability Award and EcoVadis Gold Certification
On the occasion of the annual convention of the European Rental Association (ERA), held in Madrid on 15 and 16 May 2019, LOXAM received the Sustainability Award for its corporate programme to develop its Safety culture. This unprecedented approach is one of the initiatives conducted by LOXAM as part of its CSR policy in all 22 countries in which the Group operates.
In 2018, among the key pillars of its commitment to social responsibility, LOXAM chose to place emphasis on safety, a priority for the European equipment rental leader and a major issue for everyone, anytime and anywhere. As part of this safety focus, LOXAM launched the first edition of its in-house Safety Challenge, calling on contributions from nearly 8,000 employees all over the world (22 countries on 4 continents).
Through this challenge, the company’s management intended to raise
awareness among the widest possible audience of the benefits of engaging
in a process of “co-construction” combining individual and collective
Indeed, identifying issues and setting goals for Prevention and Safety are generally the responsibility of Management. On this occasion, the spotlight was directed towards the contribution of employees as the owners of practical and theoretical knowledge in their specific disciplines who advise their customers, repair equipment and travel for their personal and occupational needs.
This large-scale exercise, the first of its kind, is a perfect
reflection of the priority that the LOXAM Group gives to safety and
illustrates its desire to involve all employees in the firm, regardless
of their job, country and culture. Safety is everyone’s business, and it
is important that employees sense this responsibility to look after
their own safety and that of other people.
This was perfectly borne out in the success of this first edition which received 272 entries from 770 participants based in France and abroad. The Challenge singled out and rewarded 28 proposals in 9 categories to improve safety everywhere and for everyone.
All the award-winning initiatives were subsequently studied in detail to determine the feasibility of their deployment across the entire Group in 2019.
This unprecedented in-house initiative conducted in the LOXAM Group is today acknowledged by the European rental community through the presentation of this ERA Sustainability Award.
LOXAM obtains EcoVadis Gold certification for its CSR policy
LOXAM has also received Gold certification from EcoVadis, the independent rating agency which assesses suppliers on sustainability and corporate social responsibility (CSR). The appraisal is based on international standards such as the United Nations Global Compact and the Global Reporting Initiative.
The Group has been ranked in the top 5% suppliers considered as the most advanced and committed to the sustainable management of the firm, whether in terms of the environment, labour, business ethics or sustainable procurement.
This accolade comes as acknowledgment of the continuous efforts of LOXAM and the commitment of its teams to all the areas falling within the scope of corporate social responsibility. LOXAM features among the firms receiving the highest ratings from EcoVadis, illustrating its compliance with the most stringent sustainability standards.
About the LOXAM Group
N° 1 in Europe and n° 5 in the world, LOXAM is the market leader in the rental of equipment and tools for building and public works, industry, landscaping and services. With sales of €1.5 billion in 2018, 760 branches and 7,900 employees, the Group is established in 13 countries in Europe (Belgium, Denmark, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Switzerland, United Kingdom), the Middle East, Morocco, Brazil and Colombia. LOXAM has the largest machine fleet in Europe, with more than 350,000 items of equipment to anticipate, support and fulfil the growing demand from companies that wish to outsource the procurement, management and maintenance of their equipment.
Virginie Adam: +33 1 41 38 95 20
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
bitFlyer Europe and Quazard Partner to Bring First Ever Trading Competition to Botwars Ultimate Trading1.6.2020 07:00:00 EEST | Press release
Leading cryptocurrency exchange bitFlyer, is partnering with crypto-trading game developer Quazard, to bring the first ever gamified trading competition to the Botwars Ultimate Trading universe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200531005005/en/ bitFlyer and Quazard bring the first gamified trading competition to the Botwars Ultimate Trading universe (Graphic: Business Wire) The competition, which launches today, allows Botwars players to compete in a free to enter crypto-trading simulator to win real Bitcoin. This is the first trading competition to launch on Botwars, and the only live trading competition of its type. In Botwars Ultimate Trading, players need to build an army of trading robots (each representing a trade) and lead them into battle to conquer the cryptocurrency markets. Botwars is a real-time, gamified currency trading experience where you will learn new trading skills, unlock powerful new tradin
Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time1.6.2020 04:00:00 EEST | Press release
Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19. The treatment was also able to show improvement in lung lesions to a normal activity level in animal models. The pre-clinical study was conducted in an animal model in collaboration with one of the Korean National Universities, Chungbuk National University College of Medicine. The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment. In comparison to the placebo-controlled group, the research team observed improved recovery in terms of clinical symptom scores such as runny nose, cough and body aches, after the first day of treatment. From the fifth day, significant clinical remission was observed. Reverse transcriptase polymerase chain reaction (RT-PCR) measurement and cell culture-based viral diagnosis were used to a
Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EEST | Press release
Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu
Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom